RxDoctor Payments Data

Jeffrey Dunn, MD

Neurology · Stanford, CANPI 1639123383

Payments from drug & device makers

$1,177,493in general payments, 2019–2025

Across 496 payments — averaging $2373.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • F. Hoffmann-la Roche AG$544K
  • Janssen Research & Development, LLC$196K
  • AstraZeneca$88K
  • Genentech USA, Inc.$88K
  • Sanofi$62K
  • Bristol Myers Squibb$42K
  • plus $157K from 12 others

What the payments were for

  • Consulting fees$154,05135%
  • Speaking & faculty fees$221,11351%
  • Travel & lodging$49,59011%
  • Food & beverage$12,3493%
  • Education$100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,177,493 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$29,484
Medicare patients
100
Services billed
171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate25$211,457
Dalfampridine ErDalfampridine37$14,555
Tramadol Hcl ErTramadol Hcl11$949
Baclofen31$792
Gabapentin17$303
Tizanidine Hcl12$196
Pramipexole DihydrochloridePramipexole Di-Hcl16$39

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$30,561$211,45725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.

Other neurology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →